Embecta Stock Earnings Reports

Embecta reported fiscal Q1 2026 revenue of ~$261M, essentially flat year-over-year (0.3% decline reported; -2% on adjusted constant currency). Key drivers: US weakness (≈7.6% adjusted constant currency decline) from lower pricing and channel/contract dynamics, while international (EMEA and Latin America) grew (~4.6% adjusted constant currency). Pen needles were down ~4.4% (impacted by US and China), syringes up ~5.3%, safety products up ~7.3%, and contract manufacturing down ~16.7% due to BD insourcing. The company has completed ~95% of its North American brand transition and is moving global transitions through calendar 2026. Management reaffirmed fiscal 2026 guidance (revenue $1.071B–$1.093B; adjusted operating margin 29–30%; adjusted EPS $2.80–$3.00) but now expects to be closer to the lower end driven by incremental US pricing headwinds; FX is a modest tailwind (~1.2%). Financials: Q1 adjusted gross margin ~62.6%; adjusted operating margin ~30.4%; adjusted EPS $0.71 for the quarter; generated ~$17M free cash flow in Q1, repaid ~$38M debt, and reduced last‑twelve‑months net leverage to ~2.8x (well under covenant). Management emphasized the seed‑growth phase priorities: strengthening the core, selective portfolio expansion (market‑appropriate pen needles/syringes), advancing GLP‑1 co‑packaging and pen injector work, and disciplined capital allocation. They are collaborating with 30+ pharma partners on GLP‑1 co‑packaging (over one‑third already selected as suppliers), see generic GLP‑1 launches beginning in some markets in 2026, and maintain confidence in a previously disclosed $100M+ GLP‑1 opportunity (by 2033) while noting timing depends on partner approvals and patent expirations. Management expects first‑half 2026 revenue to be lighter than previously assumed (≈46% of year) and a stronger second half (>50%) due to international strength.